Companies › Prevail Therapeutics
3 active drug programs in 5 registered trials: 5 Phase 1; Neurology, Metabolic and endocrine; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LY3884961 Recombinant adeno-associated virus (AAV) vector delivering GBA gene | GBA | Phase 1 | Gaucher Disease, Type 2; Gaucher Disease; Parkinson Disease | Feb 2027 |
| LY3884963 Gene therapy delivering PGRN (progranulin) to increase progranulin protein levels | GRN | Phase 1 | Frontotemporal Dementia | Nov 2029 |
| LY3962681 | – | Phase 1 | Parkinson's Disease | Jul 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04411654 | LY3884961 | Phase 1 | Gaucher Disease, Type 2 | Metabolic and endocrine | Feb 2027 |
| NCT04408625 | LY3884963 | Phase 1 | Frontotemporal Dementia | Neurology | Nov 2029 |
| NCT06565195 | LY3962681 | Phase 1 | Parkinson's Disease | Neurology | Jul 2030 |
| NCT05487599 | LY3884961 | Phase 1 | Gaucher Disease | Metabolic and endocrine | Aug 2031 |
| NCT04127578 | LY3884961 | Phase 1 | Parkinson Disease | Neurology | Aug 2031 |
Lingyi Biotech Spur Therapeutics Azafaros Bial R&D Investments AviadoBio Voyager Therapeutics Passage Bio
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.